Intuitive Surgical (NASDAQ:ISRG – Get Free Report) and Trinity Biotech (NASDAQ:TRIB – Get Free Report) are both healthcare companies, but which is the superior stock? We will compare the two businesses based on the strength of their risk, institutional ownership, earnings, dividends, analyst recommendations, valuation and profitability.
Valuation & Earnings
This table compares Intuitive Surgical and Trinity Biotech”s gross revenue, earnings per share and valuation.
| Gross Revenue | Price/Sales Ratio | Net Income | Earnings Per Share | Price/Earnings Ratio | |
| Intuitive Surgical | $11.03 billion | 11.24 | $2.86 billion | $8.73 | 40.22 |
| Trinity Biotech | $43.78 million | 0.15 | -$37.38 million | ($44.26) | -0.19 |
Profitability
This table compares Intuitive Surgical and Trinity Biotech’s net margins, return on equity and return on assets.
| Net Margins | Return on Equity | Return on Assets | |
| Intuitive Surgical | 28.45% | 16.91% | 14.83% |
| Trinity Biotech | -70.06% | N/A | -32.13% |
Risk & Volatility
Intuitive Surgical has a beta of 1.47, indicating that its stock price is 47% more volatile than the S&P 500. Comparatively, Trinity Biotech has a beta of 0.74, indicating that its stock price is 26% less volatile than the S&P 500.
Analyst Ratings
This is a summary of current ratings and price targets for Intuitive Surgical and Trinity Biotech, as provided by MarketBeat.
| Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
| Intuitive Surgical | 1 | 8 | 22 | 0 | 2.68 |
| Trinity Biotech | 1 | 0 | 0 | 0 | 1.00 |
Intuitive Surgical presently has a consensus price target of $508.68, indicating a potential upside of 44.86%. Given Intuitive Surgical’s stronger consensus rating and higher probable upside, analysts plainly believe Intuitive Surgical is more favorable than Trinity Biotech.
Insider and Institutional Ownership
83.6% of Intuitive Surgical shares are held by institutional investors. Comparatively, 79.0% of Trinity Biotech shares are held by institutional investors. 0.6% of Intuitive Surgical shares are held by company insiders. Comparatively, 8.2% of Trinity Biotech shares are held by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company will outperform the market over the long term.
Summary
Intuitive Surgical beats Trinity Biotech on 13 of the 14 factors compared between the two stocks.
About Intuitive Surgical
Intuitive Surgical, Inc. develops, manufactures, and markets products that enable physicians and healthcare providers to enhance the quality of and access to minimally invasive care in the United States and internationally. The company offers the da Vinci Surgical System that enables complex surgery using a minimally invasive approach; and Ion endoluminal system, which extends its commercial offerings beyond surgery into diagnostic procedures enabling minimally invasive biopsies in the lung. It also provides a suite of stapling, energy, and core instrumentation for its multi-port da Vinci surgical systems; progressive learning pathways to support the use of its technology; infrastructure of service and support specialists, a complement of services to its customers, including installation, repair, maintenance, 24/7 technical support, and proactive system health monitoring; and integrated digital capabilities providing connected offerings, streamlining performance for hospitals with program-enhancing insights. The company sells its products through direct sales organizations, such as capital and clinical sales teams. It has a collaboration agreement with FluoGuide A/S for head & neck cancer. The company was incorporated in 1995 and is headquartered in Sunnyvale, California.
About Trinity Biotech
Trinity Biotech plc acquires, together with its subsidiaries, develops, acquires, manufactures, and markets medical diagnostic products for the clinical laboratory and point-of-care (POC) segments of the diagnostic market in the Americas and Ireland. The company offers clinical laboratory products, including diagnostic tests and instrumentation, which detects infectious diseases; sexually transmitted diseases consisting of syphilis and herpes; SARS-CoV-2; and epstein barr, measles, mumps, toxoplasmosis, cytomegalovirus, rubella, varicella and other viral pathogens, as well as products for the in-vitro diagnostic testing for haemoglobin A1c used in the monitoring and diagnosis of diabetes, and identifying those who are at a risk of developing diabetes. It also provides laboratory-testing services for Sjogren's syndrome, hearing loss, celiac disease, lupus, rheumatoid arthritis, systemic sclerosis, and other laboratory-testing services for autoimmune disorders. The company develops, manufactures, and sells products in the immunofluorescence assay, enzyme-linked immunosorbent, western blot, and line immunoassay formats; and provides reagent products, such as ACE, bile acids, oxalate, and glucose-6-phosphate dehydrogenase for diagnosis of liver and kidney diseases, as well as haemolytic anaemia. It serves public health authorities, non-governmental organisations, and clinical and reference laboratories through its direct sales force, as well as through a network of independent distributors and strategic partners. Trinity Biotech plc was incorporated in 1992 and is headquartered in Bray, Ireland.
Receive News & Ratings for Intuitive Surgical Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Intuitive Surgical and related companies with MarketBeat.com's FREE daily email newsletter.
